Kim et al. found negative IMP3 expression in dysplasia and chronic cholecystitis specimens while 87.7% of GBC expressed IMP3 immunoreactivity, concluding that IMP3 is a useful diagnostic marker for GBC. Here, IMP3 is linked to dysplasia.